August 20, 2021
Article
STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.
August 17, 2021
The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.
August 03, 2021
The OVATION 2 study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with stage 3 and 4 ovarian cancer.
June 11, 2021
Video
Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.
May 25, 2021
This discovery could enhance efforts to develop better treatments for breast, ovarian, and prostate cancer.
April 16, 2021
Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.
April 13, 2021
The safety profile was consistent with the profiles associated with each drug as a monotherapy, with no clinically significant drug-drug interactions observed with the combination.
April 08, 2021
Study indicates patients with ovarian cancer frequently receive aggressive end-of-life care despite industry guidelines that emphasize quality of life for those with advanced disease.
April 06, 2021
Guidelines typically recommend debulking surgery, plus systemic chemotherapy for most patients.
March 23, 2021
The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.
